vs
Idexx Laboratories（IDXX）とRB GLOBAL INC.（RBA）の財務データ比較。上の社名をクリックして会社を切り替えられます
RB GLOBAL INC.の直近四半期売上が大きい（$1.2B vs $1.1B、Idexx Laboratoriesの約1.1倍）。Idexx Laboratoriesの純利益率が高く（22.8% vs 9.1%、差は13.6%）。Idexx Laboratoriesの前年同期比売上増加率が高い（14.3% vs 5.4%）。Idexx Laboratoriesの直近四半期フリーキャッシュフローが多い（$326.3M vs $186.5M）。過去8四半期でIdexx Laboratoriesの売上複合成長率が高い（6.4% vs 6.3%）
IDEXXラボラトリーズは1983年設立の米国多国籍企業で、伴侶動物獣医療、家畜・家禽、水質検査、乳製品分野向けの製品・サービスの開発・製造・流通を手がけています。本社はメイン州ウェストブルックにあり、EMEA地域の拠点はオランダのホーフドルプに置かれています。
リッチーブラザーズオークショニア（証券コードRBA）はカナダに登記されている上場企業で、本社は米国イリノイ州ウェストチェスターに所在し、普通株式はトロント証券取引所とニューヨーク証券取引所の両方で取引されています。
IDXX vs RBA — 直接比較
売上が大きい
RBA
1.1倍大きい
$1.1B
売上成長率が高い
IDXX
+8.9%の差
5.4%
純利益率が高い
IDXX
純利益率が13.6%高い
9.1%
フリーキャッシュフローが多い
IDXX
FCF $139.8M多い
$186.5M
2年売上CAGRが高い
IDXX
2年複合成長率
6.3%
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.1B | $1.2B |
| 純利益 | $248.2M | $109.7M |
| 粗利率 | 60.3% | — |
| 営業利益率 | 28.9% | 14.7% |
| 純利益率 | 22.8% | 9.1% |
| 売上前年比 | 14.3% | 5.4% |
| 純利益前年比 | 14.8% | -7.4% |
| EPS（希薄化後） | $3.09 | $0.53 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上IDXXRBA
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $998.4M | $1.1B | ||
| Q4 24 | $954.3M | $1.1B | ||
| Q3 24 | $975.5M | $981.8M | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $964.1M | $1.1B |
純利益IDXXRBA
| Q4 25 | $248.2M | $109.7M | ||
| Q3 25 | $274.6M | $95.5M | ||
| Q2 25 | $294.0M | $109.8M | ||
| Q1 25 | $242.7M | $113.4M | ||
| Q4 24 | $216.1M | $118.5M | ||
| Q3 24 | $232.8M | $76.1M | ||
| Q2 24 | $203.3M | $111.1M | ||
| Q1 24 | $235.6M | $107.4M |
粗利率IDXXRBA
| Q4 25 | 60.3% | — | ||
| Q3 25 | 61.8% | — | ||
| Q2 25 | 62.6% | — | ||
| Q1 25 | 62.4% | — | ||
| Q4 24 | 59.8% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 61.7% | — | ||
| Q1 24 | 61.5% | — |
営業利益率IDXXRBA
| Q4 25 | 28.9% | 14.7% | ||
| Q3 25 | 32.1% | 14.5% | ||
| Q2 25 | 33.6% | 15.9% | ||
| Q1 25 | 31.7% | 17.1% | ||
| Q4 24 | 27.4% | 18.1% | ||
| Q3 24 | 31.2% | 15.6% | ||
| Q2 24 | 26.3% | 18.4% | ||
| Q1 24 | 31.0% | 18.7% |
純利益率IDXXRBA
| Q4 25 | 22.8% | 9.1% | ||
| Q3 25 | 24.8% | 8.7% | ||
| Q2 25 | 26.5% | 9.3% | ||
| Q1 25 | 24.3% | 10.2% | ||
| Q4 24 | 22.7% | 10.4% | ||
| Q3 24 | 23.9% | 7.8% | ||
| Q2 24 | 20.3% | 10.1% | ||
| Q1 24 | 24.4% | 10.1% |
EPS（希薄化後）IDXXRBA
| Q4 25 | $3.09 | $0.53 | ||
| Q3 25 | $3.40 | $0.43 | ||
| Q2 25 | $3.63 | $0.53 | ||
| Q1 25 | $2.96 | $0.55 | ||
| Q4 24 | $2.62 | $0.58 | ||
| Q3 24 | $2.80 | $0.36 | ||
| Q2 24 | $2.44 | $0.54 | ||
| Q1 24 | $2.81 | $0.53 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.1M | $531.5M |
| 総負債低いほど良い | $450.0M | $2.3B |
| 株主資本純資産 | $1.6B | $5.6B |
| 総資産 | $3.4B | $12.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.28× | 0.42× |
8四半期トレンド — 暦四半期で整列
現金・短期投資IDXXRBA
| Q4 25 | $180.1M | $531.5M | ||
| Q3 25 | $208.2M | $674.7M | ||
| Q2 25 | $164.6M | $710.2M | ||
| Q1 25 | $164.0M | $578.1M | ||
| Q4 24 | $288.3M | $533.9M | ||
| Q3 24 | $308.6M | $650.7M | ||
| Q2 24 | $401.6M | $599.5M | ||
| Q1 24 | $397.4M | $462.8M |
総負債IDXXRBA
| Q4 25 | $450.0M | $2.3B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.6B | ||
| Q4 24 | $617.8M | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.8B | ||
| Q1 24 | — | $2.9B |
株主資本IDXXRBA
| Q4 25 | $1.6B | $5.6B | ||
| Q3 25 | $1.6B | $5.5B | ||
| Q2 25 | $1.5B | $5.5B | ||
| Q1 25 | $1.4B | $5.3B | ||
| Q4 24 | $1.6B | $5.2B | ||
| Q3 24 | $1.6B | $5.2B | ||
| Q2 24 | $1.6B | $5.2B | ||
| Q1 24 | $1.6B | $5.1B |
総資産IDXXRBA
| Q4 25 | $3.4B | $12.1B | ||
| Q3 25 | $3.4B | $12.2B | ||
| Q2 25 | $3.3B | $12.2B | ||
| Q1 25 | $3.2B | $11.9B | ||
| Q4 24 | $3.3B | $11.8B | ||
| Q3 24 | $3.4B | $11.9B | ||
| Q2 24 | $3.4B | $12.1B | ||
| Q1 24 | $3.4B | $12.0B |
負債/資本比率IDXXRBA
| Q4 25 | 0.28× | 0.42× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | 0.39× | 0.50× | ||
| Q3 24 | — | 0.52× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | — | 0.58× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $355.8M | $255.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $326.3M | $186.5M |
| FCFマージンFCF / 売上 | 29.9% | 15.5% |
| 設備投資強度設備投資 / 売上 | 2.7% | 5.7% |
| キャッシュ転換率営業CF / 純利益 | 1.43× | 2.33× |
| 直近12ヶ月FCF直近4四半期 | $1.1B | $719.2M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローIDXXRBA
| Q4 25 | $355.8M | $255.2M | ||
| Q3 25 | $402.3M | $239.7M | ||
| Q2 25 | $185.7M | $326.5M | ||
| Q1 25 | $238.0M | $156.8M | ||
| Q4 24 | $262.0M | $184.5M | ||
| Q3 24 | $220.1M | $285.4M | ||
| Q2 24 | $248.3M | $337.3M | ||
| Q1 24 | $198.6M | $124.8M |
フリーキャッシュフローIDXXRBA
| Q4 25 | $326.3M | $186.5M | ||
| Q3 25 | $371.2M | $188.5M | ||
| Q2 25 | $151.6M | $241.7M | ||
| Q1 25 | $207.9M | $102.5M | ||
| Q4 24 | $232.8M | $127.9M | ||
| Q3 24 | $192.0M | $248.5M | ||
| Q2 24 | $215.0M | $308.6M | ||
| Q1 24 | $168.3M | $79.6M |
FCFマージンIDXXRBA
| Q4 25 | 29.9% | 15.5% | ||
| Q3 25 | 33.6% | 17.3% | ||
| Q2 25 | 13.7% | 20.4% | ||
| Q1 25 | 20.8% | 9.2% | ||
| Q4 24 | 24.4% | 11.2% | ||
| Q3 24 | 19.7% | 25.3% | ||
| Q2 24 | 21.4% | 28.2% | ||
| Q1 24 | 17.5% | 7.5% |
設備投資強度IDXXRBA
| Q4 25 | 2.7% | 5.7% | ||
| Q3 25 | 2.8% | 4.7% | ||
| Q2 25 | 3.1% | 7.2% | ||
| Q1 25 | 3.0% | 4.9% | ||
| Q4 24 | 3.1% | 5.0% | ||
| Q3 24 | 2.9% | 3.8% | ||
| Q2 24 | 3.3% | 2.6% | ||
| Q1 24 | 3.1% | 4.2% |
キャッシュ転換率IDXXRBA
| Q4 25 | 1.43× | 2.33× | ||
| Q3 25 | 1.47× | 2.51× | ||
| Q2 25 | 0.63× | 2.97× | ||
| Q1 25 | 0.98× | 1.38× | ||
| Q4 24 | 1.21× | 1.56× | ||
| Q3 24 | 0.95× | 3.75× | ||
| Q2 24 | 1.22× | 3.04× | ||
| Q1 24 | 0.84× | 1.16× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
IDXX
| Vet Lab Consumables | $389.0M | 36% |
| Reference Laboratory Diagnostic And Consulting Services | $349.2M | 32% |
| Rapid Assay Products | $76.0M | 7% |
| Recurring Revenue | $70.6M | 6% |
| CAG Diagnostic Capital Instruments | $58.1M | 5% |
| Water Segment | $50.5M | 5% |
| Livestock And Poultry Diagnostics Segment | $37.5M | 3% |
| CAG Diagnostics Service And Accessories | $35.3M | 3% |
| Systems And Hardware | $20.1M | 2% |
| Rebate And Up Front Considerations Arrangements | $2.4M | 0% |
| Extended Warranties And Post Contract Support Revenue | $1.0M | 0% |
RBA
| Buyer Revenue | $577.2M | 48% |
| Seller Revenue | $255.2M | 21% |
| CA | $199.0M | 17% |
| Other | $124.7M | 10% |
| AU | $47.3M | 4% |
